CHARTWELL NEWS
  • KENT EASTMAN JOINS SIMMONS BANK AS EVP, TEXAS PRESIDENT

    Chartwell Partners is pleased to announce that Kent Eastman recently joined Simmons Bank as EVP, Texas President. In this role, Eastman will be responsible for growing and leading Simmons’ Texas market expansion. Simmons has a significant presence in Texas and plans to continue to expand across the state.   Prior to joining Simmons Bank, Eastman…

  • JOSEPH “JODY” MULLINGS JOINS CITY BANK AS MARKET PRESIDENT, EL PASO

    The Financial Services Practice at Chartwell Partners is pleased to announce that Jody Mullings has joined City Bank as Market President, El Paso.  A veteran El Paso banking executive, Mullings has over 35 years of banking experience, most recently as Market President at Bank of Texas.  As Market President for City Bank’s El Paso market,…

  • BioCryst Pharmaceuticals Appoints Salisa Hauptmann, MPH as SVP, Regulatory Affairs

    Chartwell Partners is pleased to announce the appointment of Salisa Hauptmann, MPH, as Senior Vice President, Regulatory Affairs for BioCryst Pharmaceuticals, a company pioneering the discovery, development and commercialization of oral, small molecule medicines to treat rare diseases. Salisa brings more than 25 years of global regulatory expertise to BioCryst, including significant work with rare,…

  • Addus HomeCare adds Veronica Hill-Milbourne and Esteban López, M.D. to their Board of Directors

    Chartwell Partners is pleased to announce that Veronica Hill-Milbourne and Esteban López, M.D. have been appointed to Addus HomeCare’s Board of Directors.   Ms. Hill-Milbourne is currently President and Chief Executive Officer of Spectrum Health Services, Inc., with executive oversight of three Federally Qualified Health Centers located in Philadelphia, Pennsylvania. She previously served as Chief…

  • Rare Disease Biotech Company, EryDel, names Esin Kosal, PhD as SVP, Regulatory Affairs

    Chartwell Partners is pleased to announce the recruitment of Esin Kosal, PhD as SVP, Regulatory Affairs for EryDel SpA, a global biotechnology company utilizing its proprietary red blood cell drug delivery technology to encapsulate small and large molecules into a patient’s own red blood cells which are then reinfused into that patient in a fast,…